Becton, Dickinson and Company (BDX.VI)
Vienna - Vienna Delayed price. Currency in EUR
Add to watchlist
At close: 05:32PM CEST
| Previous close | 218.60 |
| Open | 216.00 |
| Bid | 215.60 x N/A |
| Ask | 217.40 x N/A |
| Day's range | 216.50 - 217.60 |
| 52-week range | 205.90 - 261.00 |
| Volume | |
| Avg. volume | 1 |
| Market cap | 62.57B |
| Beta (5Y monthly) | 0.46 |
| PE ratio (TTM) | 49.32 |
| EPS (TTM) | 4.39 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | 3.55 (1.64%) |
| Ex-dividend date | 10 June 2024 |
| 1y target est | N/A |
ZacksBD's (BDX) New Research Tool to Aid Single-Cell Analysis
BD (BDX) announces the commercial launch of its new single-cell research tool, BD Rhapsody ATAC-Seq Assay, to help researchers understand DNA regulation.
PR NewswireNew BD Research Tool Helps Scientists Study Cells that are Often Key Culprits in the Development of Cancer and Infectious Diseases
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial launch of a new single-cell research tool to help scientists better understand how the molecular machinery within a cell functions and how it regulates changes in a cell that can lead to cancer and other diseases.
PR NewswireBD Announces Dates for Third Quarter and Fourth Quarter Fiscal 2024 Earnings Webcasts
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it plans to host webcasts to discuss quarterly financial results on the following dates:
© 2024 Yahoo. All rights reserved.